Epilepsy is a serious neurological disorder and characterized by recurrent and unprovoked seizures. A critical pathological factor in the seizure genesis is neuronal loss. However, mechanisms which lead to neuronal death remain elusive. Our present investigation depicted that ferroptosis, a recently discovered iron-and lipid peroxidation-dependent cell death, probably served as a mechanism in murine models of kainic acid (KA)-induced seizures. And treatment with ferroptosis inhibitors ferrostatin-1 (Fer-1), liproxstatin-1 (Lipo-1) or deferoxamine (DFO) significantly suppressed seizure severity and frequency. Using gene expression profiling in HT22 cells after glutamate exposure (a validated ferroptotic cell death model), we identified lysyl oxidase (Lox) as a novel inducer of ferroptosis. Mechanistically, Lox promoted ferroptosis via activation of extracellular regulated protein kinase (ERK)-dependent 5-lipoxygenase (Alox5) phosphorylation at serine 663 residue signaling, subsequent leading to lipid reactive oxygen species (ROS) accumulation. In a murine model of KA-induced seizure, we illustrated that administration of β -aminopropionitrile (BAPN), a specific Lox inhibitor, remarkably prevented seizure generation. Overall, these findings highlight Lox, a novel identified ferroptotic regulator in neurons, serves as a potential target for seizure-related disease including epilepsy.
Introduction
Epilepsy is by far the most prevalent serious neurological disorder worldwide, affecting nearly 50 million people. It is often featured by an enduring propensity for generation of unprovoked epileptic seizures in the vulnerable brain area including hippocampus (1, 2) and the associated neurological comorbidities such as cognitive deterioration, psychological and social consequences, finally seriously affecting the life quality of epileptic patients. Seizure is a common phenomenon in the etiology of epilepsy and it is well known that severe and repetitive seizures can result in activation of neuronal death pathways (2) . In fact, hippocampal neuronal loss always occurs in epileptogenic foci (3) . However, the potential molecular mechanism of neuronal loss remains enigmatic. It was previously unequivocally reported that seizure-activated neuronal cell death pathway could lead to progressive hippocampal neuronal loss and cognition deficits (4) . Deciphering the molecular pathways underlying seizure-induced neuronal death is invaluable to the development of novel therapeutic approaches for protecting the brain against prolonged or repetitive seizures during epileptogenesis.
Classically, neuronal death modality has been divided into two major forms: apoptosis and necrosis, on the basis of their distinct morphological, biochemical and molecular attributes. Apoptosis is a sort of programmed cell death while necrosis is considered to be uncontrolled (5) . More recently, there is now evidence supporting that necrosis can be regulated by genetic and pharmacological ways, which is called "regulated necrosis" (6) (7) (8) . Nowadays, multiple paradigms of regulated necrosis process have been discovered, including necroptosis, pyroptosis and ferroptosis (9) (10) (11) .
Ferroptosis is a recently discovered form of regulated cell death (RCD) which differs from other cell death modes by its characteristics of mitochondrial shrinkage and condensed membrane density (morphological), iron-dependent lethal lipid-based reactive oxygen species (ROS) overproduction, particularly lipid hydroperoxide (biochemical) and involvement of unique execution mechanisms (11) . Lipid peroxidation is a critical feature in the ferroptosis execution. There is ample evidence supporting that various modulators of lipid metabolism including Acyl-CoA synthetase long-chain family 4 (ACSL4), glutathione peroxidase 4 (GPX4), 5-lipoxygenase (Alox5), Alox12 and phosphatidyletha-nolamine-binding protein 1 (PEBP1) are involved in ferroptotic cell death (12) (13) (14) (15) (16) . For instance, it has demonstrated that an enhanced Alox5 activity has been found in ferroptosis process under glutamate-triggered neurotoxicity in hippocampal neurons and pharmacological inhibition of Alox5 by Zileuton counteracts ferroptotic death event in this model (14) .
Nowadays, ferroptosis has been extensively reported in multiple pathogenic conditions including cancers (17) (18) (19) , neurological disorders (20, 21) and renal failure (13) . Particularly, our recent publications (22, 23) have unequivocally proved the occurrence of ferroptosis in various chemical reagents-induced epileptic rodent models. And treatment with ferroptosis inhibitors (ferrostatin-1 (Fer-1) or liproxstatin-1 (Lipo-1)) efficiently alleviates seizures, highlighting a crucial role of ferroptosis process in seizure generation. In this respect, a deep understanding of the potential mechanisms that regulate ferroptosis might provide alternative therapeutic targets for treating seizure-associated disorders including epilepsy.
In our present work, it is revealed that ferroptosis is present in a mouse model of kainic acid (KA)-induced seizures and human epilepsy. And treatment with ferroptosis inhibitors Fer-1, Lipo-1 or Deferoxamine (DFO) evidently alleviates epileptic seizures in mice. Furthermore, using gene expression profile, we identify and validate lysyl oxidase (Lox), a copper-dependent monoamine enzyme in the extracellular matrix (ECM) remodeling, as a novel ferroptotic inducer in vitro hippocampal HT22 neuron ferroptosis models caused by glutamate or erastin.
Pharmacological inhibition of Lox by a specific inhibitor
β -aminopropionitrile (BAPN) prominently ameliorates epileptic seizures.
Lox is initially responsible for the catalysis of cross-linking of elastin and collagens in the ECM (24) . Previous investigations have indicated its contribution to tumor metastasis and pathogenesis of hypertension (25, 26 
Results
Ferroptosis is activated in KA-induced seizure mice and human epileptic patients. Our prior work showed the presence of ferroptosis in various epileptic seizure models induced by chemical reagents including pentylenetetrazol, pilocarpine and FeCl 3 (22, 23) . To determine whether ferroptosis process was activated in KA-induced seizures, a common model resembling human intractable epilepsy, we detected a set of ferroptotic indices in the hippocampus of this model including morphological characteristics of mitochondrion, lipid peroxidation by-products including 4-HNE and MDA levels and Ptgs2 mRNA. It was noteworthy that smaller and more condensed mitochondria ( Figure 1A ) and elevated levels of 4-HNE ( Figure 1B and Figure 1C ), MDA ( Figure 1D ) and Ptgs2 mRNA ( Figure 1E ) were found in mice subjected to KA-induced seizure, which fit the major criteria for ferroptosis. Besides, Ptgs2
mRNA level was also observed to be significantly augmented in brain tissue samples of human epilepsy compared with non-epileptic patients ( Figure 1F ). Collectively, these findings implicate that ferroptosis occurs in a mouse model of KA-induced seizures and epileptic patients. (Figure 2A ). Intriguingly, it was observed that Fer-1, Lipo or DFO all remarkably ameliorated seizure behavior ( Figure 2B and Supplementary Video). In details, seizure score ( Figure 2D ) and number of seizures within 90 min ( Figure 2E ) were both prominently decreased in KA-triggered seizures in mice when treatment with Fer-1, Lipo-1 or DFO, despite no significant difference for seizure latency ( Figure 2C ). These data suggest that blockade of ferroptosis has potential therapeutic value for seizure control.
Suppression of ferroptosis process improves phenotype in a mouse model of
Lox functions as a novel ferroptosis contributor in glutamate-induced oxidative toxicity in hippocampal HT22 neurons. To further probe the potential molecular mechanism underling the involvement of ferroptosis in seizures, we firstly established a model with glutamate-induced oxidative toxicity in the immortalized HT22 hippocampal neurons. HT22 has the feature of deficient ionotropic glutamate receptors (27) and has been considered to be an excellent model for the study of glutamate-mediated oxidative impairment. As shown in Figure 3A Figure S1 ). In glutamate-induced oxidative toxicity in HT22 cells, ferroptotic cell death was also confirmed by the upregulation of Ptgs2 at mRNA level, which was recently identified as a molecular biomarker of ferroptosis (28) . Taken together, these findings indicated that ferroptosis served as a dominant cell death modality in glutamate toxicity in HT22 cells. In our subsequent work, this model was therefore employed to elucidate the molecular mechanisms leading to neuronal ferroptosis after glutamate-triggered oxidative stress in HT22 cells. Using gene expression profiles, we compared differentiated genes between glutamate (5 mM)and vehicle-treated groups. Totally, 32 differentially expressed genes were found between these two groups. For details, 14 up-regulated genes and 18 down-regulated genes were observed in glutamate-treated group, compared with vehicle group ( Figure   3F ). In the validation stage, lysyl oxidase (Lox), a key enzyme for extracellular matrix (ECM) remodeling, was selected as a novel ferroptotic inducer since it was confirmed to be remarkably increased at different time points after glutamate exposure ( Figure   3F ) and prior study depicted that Lox induced oxidative stress in pathological scenarios (25) . Additionally, evidence for the critical role of ECM in ferroptosis arise from the fact showing that α 6β4 integrin-deficient cells are more vulnerable to ferroptosis (29) . Lox protein level and Lox activity were further found to be enormously elevated in glutamate-treated group in a time-dependent manner ( Figure   3G and Figure 3H ). Consistently, enhanced mRNA and protein levels and activity of Lox were also verified in HT22 cells treated with erastin, a specific ferroptosis inducer (Supplementary Figure S2) , while other Lox family members including Loxl1, Loxl3 and Loxl4 were all unchanged at transcriptional level either in glutamate-or erastin-induced neuronal ferroptosis (Loxl2 mRNA was undetectable) (Supplementary Figure S3 ). After knock down of Lox ( Figure 3I ) by genetic silencing, glutamate-induced cell death and lipid ROS were obviously impeded ( Figure 3J and Figure S4) . These data suggest that Lox serves as a novel ferroptosis-inducing factor in glutamate-induced oxidative toxicity in hippocampal HT22 neurons.
Erk-Alox5 axis is a major downstream signaling for the contribution of Lox to ferroptosis in glutamate toxicity in hippocampal neurons. Next, we sought to decipher the mechanism of Lox-induced ferroptosis in oxidative glutamate toxicity in neurons. Figure S5) . Collectively, these results implicate that ERK-activated Alox5 ser663 phosphorylation functions as a downstream signaling pathway of Lox-mediated ferroptotic cell death.
Pharmacological inhibition of Lox by BAPN reduces seizure activity in mice.
Subsequently, we explored whether inhibition of Lox could attenuate seizure phenotype in KA-treated mice. Expression levels of Lox mRNA and protein were confirmed to be evidently increased in the hippocampus of KA-induced epileptic seizure model ( Figure 5A , Figure 5B and Figure 5C ). We further validated that Lox was localized in neurons as evident overlapping was observed for Lox and NeuN, a specific neuronal marker ( Figure 5D ). In order to explore the role of Lox in the epileptic seizures, we investigated whether suppression of Lox by BAPN, a previously reported irreversible inhibitor (31) , could impede these pathological conditions. The experimental procedure was displayed in Figure 2A . It was found that treatment with BAPN significantly suppressed seizure behavior in KA-treated mice (and Supplementary Figure S1 ). Further data analysis revealed that seizure score and Figure 6L and Figure 6M , despite no difference in seizure latency ( Figure 6K ). Mechanistically, Lox overexpression in vivo contributed to increased phosphorylated protein levels of ERK and Alox5 (Ser663) ( Figure 6N and Figure 6O ).
These data raised the possibility that up-regulation of Lox activated ERK-dependent Alox5 Ser663 phosphorylation signaling facilitated neuronal ferroptosis in seizure-induced hippocampal damage.
Discussion
In the current work, we identify Lox as a novel neuronal ferroptosis inducer and mechanistically, ERK-Alox5 signaling serves as the downstream pathway of Lox to promote ferroptosis process in neurons. The Lox inhibitor BAPN can blunt ERK-Alox5-dependent ferroptosis process and exert potent anti-seizure potential ( Figure 7B ).
Seizures are very common in a plethora of human brain disorders including epilepsy (32), ischemic stroke (33), traumatic brain injury (23), Alzheimer's disease (34) and so on. Preventing seizure generation may have beneficial effects for curing these pathogenic conditions. It is well known that repeated seizures activate multiple cell death modes such as apoptosis (35) . Targeting neuronal apoptosis was found to ameliorate the severity of seizures in experimental epilepsy models (36) . Nevertheless, there is ample evidence supporting that treatment with the traditional anti-epileptic drugs via manipulating cell apoptosis induces many adverse reactions such as cognitive deficits and recurring seizures (37, 38) . It is likely that seizure can initiate non-apoptotic forms of regulated cell death. Our recent work has delineated that ferroptosis, a novel cell death mode, is induced in FeCl 3 -, PTZ-and pilocarpine-induced seizure models (22, 23) . Similarly, in our current study, we also only provides a previously unknown cell death mechanism suggesting that ferroptosis is activated in epileptic seizures, but also strongly implicates that reducing ferroptosis is a valid therapeutic target for seizure-related disorders such as epilepsy, ischemic stroke, traumatic brain injury and Alzheimer's disease.
The molecular mechanism that underlies ferroptosis induction has also been The Lox family has five members including Lox and Loxl1-Loxl4. They are originally considered to be copper-dependent amino oxidases which are responsible for the cross-linking of collagen and elastin, thereby imparting the tensile strength and stability of tissues (24) . Nowadays, there is substantial evidence supporting that Lox family possesses multiple biological functions, in addition to the intra-and inter-molecular cross-linking of collagen and elastin fibers. It has been shown that Lox promotes cancer migration, adhesion and metastasis in multiple types of cancers including colorectal cancer, breast cancer and lung cancer (26, 39, 40) . Blockade of Lox by a pharmacological inhibitor BAPN or CCT365623 is able to delay tumor progression and cancer metastasis (40, 41) . Moreover, the deleterious role of Lox in brain has been also observed in neuropathological states such as Alzheimer's disease and spinal cord injury (42, 43) . And pharmacological inhibition of Lox by BAPN has therapeutic effects in these disorders.
Likewise, our current data depicted elevation of Lox in both KA-induced epileptic seizures in mice and epileptic patients with hippocampal sclerosis ( Figure   5A , Figure 5B and Figure 7A (44) , which implicated that ERK-induced Alox5 activation served as a vital molecular mechanism in cellular biological process. Consistently, our present investigation also supported that elevation of phosphorylated Alox5 was found by Real-time quantitative PCR. Total RNA was extracted using TRIzol reagent (15596018, Invitrogen, USA) following the manufacturer's instructions. The procedure of real-time PCR was conducted as previously described (22) . The detailed information of primer sequences used in our study was summarized in Table 1 .
Western blotting assay. Immunoblot procedure was carried out according to our previous investigations (23) . Briefly, samples were lysed in protein lysis buffer (P0013, Beyotime Biotechnology Institue, China). Protein concentration was determined by a BCA protein assay kit (P0012, eyotime Technology Institute, China).
Western blotting was carried out with primary antibodies including Lox, 4-HNE, ERK, p-ERK, JNK, p-JNK, p38, p-p38, Alox5, p-Alox5 Ser663, β -actin or α -tubulin. The detailed information of antibodies in our present work was listed in Table 2 .
Cell culture. The immortalized hippocampal neuron HT22 was cultivated at 37
°C in a humidified 5% CO 2 atmosphere and maintained in Dulbecco's modified Eagle's medium (DMEM, Gibco) with additions of 10% fetal bovine serum (FBS, Gibco), 100U/ml penicillin and 100 μ g/ml streptomycin (Gibco).
Gene expression profile. Total RNA from each group was extracted using TRIzol reagent (Invitrogen, USA). RNA quantification was performed by the NanoDrop ND-2000 (Thermo Scientific) and RNA integrity was evaluated using Agilent Bioanalyzer 2100 (Agilent Technologies). Gene expression profiling was conducted using Affymetrix MTA1.0 arrays (Affymetrix) following the manufacturer's instructions. Differentially expressed genes were obtained with 2-fold change as well as a p value less than 0.05 between glutamate-and vehicle-treated groups.
Cell death assessment by PI/Hoechst33342 staining. The HT22 cells were cultivated in 24-well plates at 20% density. After nearly 12 h, multiple drugs were added to the cell cultures for the indicated time, and then the neurons were stained with 5 μ g/ml Propidium Iodide (PI) and 5 μ g/ml Hoechst 33342 for 5 min at 37 °C.
Cells from different groups were observed under a fluorescent microscope (Leica).
Percentage of cell death was determined by PI/(PI +Hoechst 33342).
CCK-8 assay. Cell viability was measured using a Cell Counting Kit-8 (CCK-8, Beyotime Biotechnology Institute, China). Overall, cells were incubated with 10 μ l CCK-8 reagents in 100 μ l growth medium for 2 h at 37°C. The absorbance for each sample was detected at 450 nm with a microplate reader. The results were repeated in triplicate.
Measurement of Lox activity. Lox activity was determined using a commercial assay kit (ab112139, Abcam) according to manufacturer's instructions.
Analysis of lipid ROS by fluorescence-activated cell sorting (FACS).
Detection of cellular lipid ROS was performed as previously described with minor modifications (13) . For short, HT22 cells were cultured in 6-well plates. After 12 h, cells were treated with test drugs for indicated times. Then HT22 neurons were harvested by trypsinizaiton, re-suspended in 500 μ l Hanks Balanced Salt Solution (HBSS, Gibco, USA) containing 2 μ M C11-BODIPY(581/591) (Thermo, USA) and placed at 37 °C in a cell culture incubator for 15 min. After one wash with HBSS, cells were re-suspended with fresh PBS and immediately analyzed by FACS using a flow cytometer (Beckman, USA) at an excitation wavelength of 488 nm. Data were obtained from FL1. A minimum of 20, 000 events were determined per replicate.
RNA interference. All small interfering RNAs (siRNAs) were synthesized by RioBio (RioBio, China). The target siRNA sequences were summarized in Table 1 .
Before transfection, cells were seeded in 6-well or 96-well plates and grown to a confluence of about 40%. Lipofectamine™ RNAiMAX transfection reagent was employed following the manufacturer's instructions. After 2 days of transfection, HT22 neurons were digested, passaged and cultivated in 24-well or 96-well plates, glutamate or erastin was then incubated for additional 12 h.
Confocal microscopy. For preparation of brain tissue section, animals from each group were transcardially perfused with phosphate buffer saline (PBS) followed by 4% paraformaldehyde in 0.1 M phosphate buffer (PB). The whole brains were then carefully dissected and equilibrated in 30% sucrose in PB for over 3 days at 4 °C.
Frozen tissue sections (8 µm) were collected using a cryostat (CM1900UV, Leica, Germany). For Confocal microscopic analysis, brain sections were washed in PBS for 10 min and then incubated with block solution (5% donkey serum in PBS and 0.2% Triton X-100) for 1 h at room temperature. Sections were then incubated overnight at 4°C with the primary antibody. After incubation, the slices were rinsed with PBS three times followed by incubation with the secondary antibody for 1 h. After washing, brain sections were counterstained with DAPI (1:500, Jackson Immunoresearch, USA)
for 5 min at room temperature and mounted with anti-fading medium. Fluorescent images were obtained using a confocal laser scanning microscope (Nikon, Japan). To avoid the nonspecific staining, the incubation of primary antibody was replaced with normal serum, followed by all the subsequent experiments as described above. All the primary antibodies and secondary antibodies were summarized in Table 2 . Data analysis. All the results were displayed as mean ± SD. Comparison of 2 groups was performed using the dependent Student's t test. For the comparison of more than 2 groups, we used ANOVA with the Bonferroni test. A p value of less than 0.05 was considered to be significant and was indicated *p<0.05, **p<0.01 or ***p<0.001 in the graphs. 
Figure Legends

